London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Started: Bermudashorts, 4 Sep 2023 07:28
Last post: BoracicLint, 4 Sep 2023 09:56
It seems a fair offer at £13.50 looking at recent SP history so I will be accepting that. From the RNS, they are also hoping to complete the transaction during Q1 2024.
I wasn't aware of any acquisition talks ongoing and so not aware if there is any likelihood of another bidder entering the fray.
Didn't see that coming. Ergomed has been a cracking investment and proof that holding long on AIM can work out. Look forward to watching from a distance and hope they continue to go from strength to strength.
Cheers for the link Troajan
Started: Sheephatch, 25 Jul 2023 08:00
Last post: Bermudashorts, 25 Jul 2023 12:03
Yep an impressive update, particularly in the current enviroment.
Strong growth announcement.
Let’s hope we see it reflected in the SP which has been a bit subdued.
Still a great long term investment though in my opinion.
Started: Vectis20, 28 Mar 2023 16:11
Last post: Vectis20, 28 Mar 2023 16:11
This is a frustrating investment currently. The recent results were by any parameters good, yet even allowing for the recent general market volatility, the share price has been hammered.
Pharma shares on AIM are notoriously volatile yet this isn’t a company trying to bring a drug through development or trial, their effective ‘support’ facilities to that sector are in high demand.
Future Order / Work pipeline is a big number, No debt, Cash still strong ( reduction on previous year easily explained by the Adamas acquisition).
EPS only marginally increased, perhaps the MM’s and Analysts were disappointed with that figure but that seems unlikely.
I’m nursing a bigger paper loss on this investment that I would normally tolerate, but like fellow commentators I still see this as an excellent medium term growth stock. Just currently frustrating, so guess go with the proverbial ups and downs of investing.
Started: Sheephatch, 3 Feb 2023 15:42
Last post: Sheephatch, 3 Feb 2023 15:42
Good tick up today,not sure why but I won’t complain.
Hoping to add £20,000 in here in this years ISA allowance if things go to plan and I see this as a 5-10 year investment. Very strong growth potential and with relatively little risk as far as I can see.
Interesting and a very bright future ahead in my opinion.
Started: Sheephatch, 25 Jan 2023 08:06
Last post: Vectis20, 25 Jan 2023 11:37
Yes, very solid figures. Share price today doesn't reflect that but a potential buying opportunity for those like myself who see this as a strong long term portfolio hold.
I believe their organic and acquisition growth strategy will continue, they could be a potential acquisition target themselves at some future date, although I personally don’t see that as a short / medium term possibility. IMHO
Yep another strong update.
Richard Barfield has been a great asset, I'll be sorry to see him go and wish him well in his retirement. Great succession planning though with a smooth transition to another high quality CFO.
#sell
Yep, great company. Never fails to impress.
Is this a ‘sale the news’ like so many other decent updates lately? Sigh.
Strong figures again today.
Good solid future.
Started: Sheephatch, 17 Nov 2022 15:36
Last post: Sheephatch, 17 Nov 2022 15:36
RNS this morning looks very positive.
Certainly strengthening the team and hopefully taking the company forward.
Can see the SP being 1400 plus pretty soon.
Started: Sheephatch, 4 Aug 2022 14:06
Last post: Sheephatch, 4 Aug 2022 14:06
Well we got there but it wasn’t really unexpected on the good figures supplied. Can we continue the momentum into the next few months. Difficult to say with what’s going on around us but it really should be getting back to recent highs. Good luck.
Started: Sheephatch, 29 Jul 2022 17:17
Last post: Sheephatch, 29 Jul 2022 17:17
Some pretty decent buying over the last couple of days.
Lets hope it continues next and and we see 1300 plus.
One can but hope, but in my honest opinion its actualy pretty likely in the near term.
Have a good weekend and fingers crossed for the Lionesses.
Started: Sheephatch, 26 Jul 2022 09:40
Last post: Bermudashorts, 26 Jul 2022 14:07
Excellent update today from Ergomed. strong revenue and order book growth with £12 cash after the purchase of Adamas and debt free. Note the increase in the RCF to £80m - seems they are still very much in acquisitive mode.
Excellent growth.
Hopefully the SP will return to a higher level on these rather outstanding figures.
Started: Troajan, 26 Jul 2022 11:01
Last post: Troajan, 26 Jul 2022 11:01
Started: Troajan, 29 Mar 2022 09:50
Last post: Troajan, 29 Mar 2022 09:50
Started: Sheephatch, 29 Mar 2022 09:16
Last post: Sheephatch, 29 Mar 2022 09:16
· Revenue £118.6 million up 37.3%
· Adjusted EBITDA £25.4 million up 31.2%
· Forward visibility underpinned by strong order book of £239.7 million up 24.2%
· Further strengthening of US strategic presence with US revenues up 59.5%
· Year-end net cash balance of £31.2 million up 64.5%
Strong growth in America and Asia.
Excellent progression.
Started: Sheephatch, 2 Mar 2022 13:47
Last post: Sheephatch, 2 Mar 2022 13:47
Buying pressure full on.
Started: Sheephatch, 28 Feb 2022 13:32
Last post: Sheephatch, 28 Feb 2022 13:32
People seem to be coming in again ready for results in just four weeks time. Ive added first thing this morning with another 650 shares.
Started: Sheephatch, 9 Feb 2022 08:03
Last post: Sheephatch, 9 Feb 2022 08:03
ADAMAS now part of the growth and onward direction here. Excellent addition.
Started: Sheephatch, 7 Feb 2022 14:10
Last post: Sheephatch, 7 Feb 2022 14:10
Yes it hasn't performed how I had anticipated. Generally the larger trades seem to be buying and numerous smaller trades selling. This is a longterm investment for myself and Im very happy with the books being filled and the future of this expanding company. RNS was very good.
I will be adding again shortly hopefully when I get some successful outcomes elsewhere. Happily I will be paying a lot less than perhaps I could have.
You really put a hex on it there Sheephatch!
What's happened? A very positive RNS and yet it drops over 25%.
Has anyone figured it out?
Great start to the New Year.
Things looking very strong.
Just a quick look at careers on the company website shows how they are expanding and pushing forward.
The appointment of Zizi Uzezi looks very exciting with her terrific background and brings a huge amount to experience to Ergo.
SP will continue to move up gradually in my opinion and then we could see significant jumps on updates.
Personally I will be adding at every opportunity as and when the opportunity arises.
Started: cefncribwr, 31 Dec 2021 09:35
Last post: cefncribwr, 31 Dec 2021 10:48
I think I have the answer. Nearly 3 hours' trading today and only one trade, for 790 shares. Hopefully it's down to the time of year.
The bid/offer spread is 6.71% at the moment, which is a deterrent to buyers. Is it this wide usually? Maybe it is due to low volume?
Started: Sheephatch, 29 Dec 2021 16:41
Last post: Sheephatch, 29 Dec 2021 16:41
Todays performance should hopefully put us on a few peoples radars. Lets hope this strong buying continues well into the New Year. Another set of strong results will see this heading well above previous highs.
Started: Sheephatch, 16 Dec 2021 16:04
Last post: Sheephatch, 16 Dec 2021 16:04
CINE was one certainly to get out of. Just in time.
Started: Sheephatch, 9 Dec 2021 10:05
Last post: Bermudashorts, 9 Dec 2021 17:08
Yes Ergomed has had a cracking run over recent years and has matured into a solid business with a fat order book in the safe hands of Richard Barfield.
Purchased my 2 x 250 trades this morning. Hopefully we will be looking at a continual rise from here. We know the order books are bulging and a similar growth like the previous 12 months would be very nice. I have a lot of confidence in this company and we could even see better results then expected.
Started: Sheephatch, 8 Dec 2021 11:28
Last post: Sheephatch, 8 Dec 2021 11:28
Govt possibly about to announce Plan B. ERGO offering a safe place to invest. Im moving in more funds here tomorrow after update over at RR. CINE and TUI etc, etc all in trouble for a few months.
Started: Sheephatch, 7 Dec 2021 14:03
Last post: Sheephatch, 7 Dec 2021 14:03
Some decent buying returning now. The company has very exciting plans ahead and deep pockets which will enable a number of further acquisitions shortly. Share price returning to its onwards trajectory and an time high not too far down the road.
Started: Bermudashorts, 28 Sep 2021 13:23
Last post: Bermudashorts, 28 Sep 2021 13:23
Another strong set of results -
- Total revenue growth of 38.8% over H1 2020 to £56.0 million (up 48.1% in constant currency*)
- adjusted EBITDA of £12.1 million up 33.0%
- Net new sales awards in H1 2021 increased by 50.8% over H1 2020
- Cash balance increased to £24.6 million and debt free